All News
Maintenance of Remission in ANCA-vasculitis: MAINRITSAN study.
It is well known that ANCA-associated vasculitides can be hard to control and relapses are common. The choice of maintenance therapy is rather limited and therapies are not always effective.
Read ArticleLilly Features it's Rheumatoid and Psoriasis Biologics at ACR 2016
Eli Lilly & Co. has multiple presentations planned for the upcoming Annual meeting of the ACR/ARHP in Washington starting on Sunday, November 13th.
Read ArticleJanssen's Portfolio of New Biologics Roll Out for ACR 2016
Janssen has announced the listings for it's presentations at the upcoming annual ACR/ARHP 2016 meeting in Washington.
Read ArticleRheumNow Week in Review – 4 November 2016
Dr. Jack Cush reviews highlights and reports from this week on RheumNow.com, including drug-induced cutaneous lupus, pediatric lupus being worse, new gout drug SEL-12, Gut microbiome and IgA plasmablasts, and the weakly-received new ACP guidelines on gout.
Read ArticleLymphotoxin B and Adipose Derived Stromal Cells Regulate Skin Fibrosis in Scleroderma
A possible mechanism behind the fibrosis that occurs in scleroderma has now been identified, a mechanism, researchers say, that may one day lead to a treatment for the disease.
IgA ACPA and Plasmablasts Point to Microbiome in Pre-Clinical Rheumatoid
Serum antibodies precede the development of clinical rheumatoid arthritis (RAby) by many years, and yet we still have much to learn about this preclinical phase.
Read ArticleIs There a Familial Risk to Scleroderma?
Using population based data, researchers found a 10 fold increase prevalence of SSc in first degree relatives. That equates to a relative risk of 81. Genetic factors appear to be important in the risk for scleroderma.
Read ArticleKawasaki Disease Pathogenesis Hinges on Interleukin-1
Researchers from the Toronto Hospital for Sick Children have published in the Journal of Immunology that a polymorphism in the inositol-triphosphate 3-kinase C (ITPKC) (rs28493229) is associated with the pathogenesis of Kawasaki's disease (KD).
Read ArticleEarly Intervention with Corticosteroids and IVIG is Crucial in Kawasaki Disease
The current JAMA Pediatrics issue has published a report showing that adjunctive corticosteroid therapy yielded significantly fewer coronary artery complications compared with intravenous immunoglobulin therapy alone, particularly among high-risk patients with Kawasaki disease.
Read ArticleHigher Lupus Disease Activity in First Year Postpartum
Most women with systemic lupus erythematosus (SLE) have no or little disease activity during pregnancy, but experience greater disease activity or overt flares during the first year postpartum, a Norwegian study has found.
Read ArticleGood News for Lupus Pregnancies
The Washington Post recently interviewed Dr. Eliza Chakavarty of the OMRF about the evolution in attitudes and outcomes of lupus women who wish to get pregnant.
Read ArticleReview of Herpes Zoster with Immunosuppression and Autoimmune Disease
Researchers from the University of British Columbia reported on their systematic review and meta-analysis of risk of herpes zoster (HZ) in patients receiving biologics, DMARDs and/or corticosteroids for autoimmune diseases.
Read ArticleLow-Molecular Weight Heparin Does Not Reduce Pregnancy Complications
A Lancet meta-analysis has reviewed the preventative effects of low-molecular-weight heparin (LMWH) on placenta-mediated pregnancy complications include pre-eclampsia, late pregnancy loss, placental abruption, and birth of a small-for-gestational-age (SGA) neonate.
Read ArticleEffective Interferon-Free Regimen for HCV-Cryoglobulinemic Vasculitis
Rheumatologists have been challenged to treat hepatitis C virus (HCV)-induced rheumatic disease since discovery of the virus in 1989.
Read ArticleMichelle Petri Reviews New Therapies for Lupus
In this video, Michelle Petri, MD, director of the Hopkins Lupus Center at Johns Hopkins University, discusses recent successes and challenges in the treatment of systemic lupus erythematosus, with clinical trials results ranging from "wildly positive" to "completely negative."
Read ArticleMy Take on New Ocular Screening Guidelines for Plaquenil
A recent article published by the American Academy of Ophthalmology presented new recommendations for screening of patients being managed with hydroxychloroquine that changed the previous monitoring paradigm. More importantly, it has repositioned hydroxychloroquine from one of the safest medications that rheumatologists use to a drug that can have potentially significant ocular morbidity (if used in doses greater than 5 mg per kilogram and or for prolonged periods of time).
Necrotizing Myopathy is a Unique Form of Myositis
Muscle involvement in immune-mediated necrotizing myopathy (IMNM) was more extensive compared with other inflammatory myopathies, according to a retrospective chart review.
Read ArticleLupus Nephritis Therapies Reviewed
Singh and colleagues have published a systematic review and Bayesian network metaanalyses of clinical trials of immunosuppressive drugs and corticosteroids in patients with lupus nephriti.
The Arthritis Spectrum after Lyme Infection - Something New
Symptoms attributed to chronic Lyme disease are the bane of a rheumatologist’s existence. We often see patients referred for a variety of nonspecific complaints that do not resolve after antibiotic therapy, including the so-called post-Lyme disease syndrome.
Read ArticleRheumNow Week in Review – 30 September 2016
Three new FDA approvals, proteomics, cancer, infectious risk, nonadherence and disappointing clinical trial results covered in this RheumNow Week in Review.
Read Article